Featured Trial:
Lung Cancer Treatment

Featured Trial:
Colorectal Cancer Treatment

Featured Trial:
Melanoma Imaging

Featured Trial:
Head and Neck Cancer Treatment

Clinical and Administrative Resources

Web Application Portal

Submit an Inquiry

Update My Roster Profile

Other Research Resources

Member Blog

Resources for Active Trials

Training Video Resource Library on YouTube

Mentoring Program

Group Meeting Presentations, Audit Tools, and User Groups

Specialty Presentation:
Integrating PROs in Trials

Specialty Presentation:
Implementation Science

Latest News

April 24, 2025

Categories

Press Releases

Press Release: Estimating complex immune cell structures by AI tools for survival prediction in advanced melanoma

April 17, 2025

Categories

Announcements

The tinkerer-turned-tech leader: A profile of Mitchell D. Schnall, MD, PhD

March 22, 2025

Categories

The March 2025 News from ECOG-ACRIN blog is now available

March 17, 2025

Categories

News Stories

Stem cell transplant may not be necessary in first remission for patients with mantle cell lymphoma and undetectable MRD (features EA4151)

March 5, 2025

Categories

News Stories

WATCH: Dr. Kathy Miller on how the PATINA trial (AFT-38/PrE0111) shifts the paradigm in HER2+/ER- breast cancer treatment

March 5, 2025

Categories

News Stories

LISTEN: A JAMA Network Learning podcast interview with Dr. Anand Jillella, author of the newly published results of study EA9131 in JAMA Oncology

Posts

ECOG-ACRIN Cancer Research Group Follow 8,078 6,342

Biomarker-driven medical research involving adults who have or are at risk of developing cancer

; ECOG-ACRIN Cancer Research Group @eaonc ·

20 Jun 1936095565139570877

Our latest in @Radiology_rsna: MRI-based Radiomic Features for Risk Stratification of Ductal Carcinoma in Situ in a Multicenter Setting | ECOG-ACRIN E4112 | @kalina_slavkova @DespinaKontos @jsparano @awolff Habib Rahbar et al | #DCIS #breastcancer https://pubs.rsna.org/doi/10.1148/radiol.241628

Reply on Twitter 1936095565139570877 Retweet on Twitter 1936095565139570877 1 Like on Twitter 1936095565139570877 2 Twitter 1936095565139570877

; ECOG-ACRIN Cancer Research Group @eaonc ·

20 Jun 1936091871521947969

The EAA173/DETER-SMM #ClinicalTrial is exploring new treatments for patients with high-risk #SmolderingMyeloma. Interested in learning more? Click here: https://bit.ly/eaa173detersmm cc: @nsc_natalie, @mtmdphd, @VincentRK, @NorthTxMSG

Reply on Twitter 1936091871521947969 Retweet on Twitter 1936091871521947969 3 Like on Twitter 1936091871521947969 4 Twitter 1936091871521947969

; ECOG-ACRIN Cancer Research Group @eaonc ·

20 Jun 1936076692281307197

The MM1OA-EA02 clinical study is testing a new treatment approach for patients with #AcuteMyeloidLeukemia who are age 60 or older. Learn more: https://bit.ly/mm1oa-ea02-study #AML #leukemia

Reply on Twitter 1936076692281307197 Retweet on Twitter 1936076692281307197 0 Like on Twitter 1936076692281307197 0 Twitter 1936076692281307197

About Us

The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1400 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More

Scientific Pursuits

We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More

ECOG-ACRIN by the Numbers

Active Clinical Trials

1400

Participating Institutions

International Sites

21000

Individual Members

Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).